At the Alzheimer’s Association International Conference in Vancouver, Canada July 15-19, 2012, data from the ELND005 Phase 2 trials in mild/moderate Alzheimer’s disease describing its effect on both brain scyllo-inositol and myo-inositol levels were presented. In addition, data were also presented on the effects of oral ELND005 on neuropsychiatric symptoms in the Phase 2 trials and the potential role of myo-inositol reduction.In the second quarter, Elan and Proteostasis Therapeutics, Inc. (Proteostasis) terminated their Strategic Alliance and License Agreement. Elan retains its approximate 24% equity interest in Proteostasis.
|Three Months Ended June 30||Six Months Ended June 30|
|2011 US$m||2012 US$m||2011 US$m||2012 US$m|
|1.5||—||Severance, restructuring and other costs||1.9||1.4|
|0.8||(0.1)||Facilities and other asset impairment charges||2.7||0.5|